According to recent filings covering the 90 days ending December 12, 2025, the three most significant insider holders at LENZ Therapeutics are TenPercentOwner Venture Capital Vi, L.P. Versant (1.81Mn shares), Director James W Mccollum (536.07K shares), President And CEO And Secretary Evert B. Schimmelpennink (49.20K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Biocapital, L.P. Samsara | 1,208,498 | 13 Apr, 2022 | |
| Venture Capital Vi, L.P. Versant | 1,814,726 | 02 Oct, 2025 | |
| Davis Jerel | 243,965 | 01 Jul, 2021 | |
| Capital Management, L.P. Ra | 99,253 | 25 Mar, 2024 | |
| James W Mccollum | 536,065 | 10 Nov, 2025 | |
| Phil Gutry | Chief Business Officer | 42,850 | 13 Apr, 2022 |
| Marc Odrich | Chief Medical Officer | 14,229 | 25 Mar, 2024 |
| Evert B. Schimmelpennink | President And CEO And Secretary | 49,200 | 07 Mar, 2025 |
| Daniel R. Chevallard | Chief Financial Officer | 5,386 | 07 Nov, 2025 |
| Shawn Olsson | Chief Commercial Officer | 4,733 | 19 Nov, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 17 Nov, 2025 | Shawn Olsson | Common Stock | A | 10,000 | $2.08 | 14,733 | D | M |
| 17 Nov, 2025 | Shawn Olsson | Common Stock | D | 4,212 | $25.74 | 10,521 | D | S |
| 17 Nov, 2025 | Shawn Olsson | Common Stock | D | 5,788 | $26.37 | 4,733 | D | S |
| 07 Nov, 2025 | Daniel R. Chevallard | Common Stock | A | 20 | $22.71 | 3,208 | D | P |
| 07 Nov, 2025 | James W Mccollum | Common Stock | A | 10,500 | $22.79 | 10,500 | D | P |
| 07 Nov, 2025 | Daniel R. Chevallard | Common Stock | A | 2,178 | $22.76 | 5,386 | D | P |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | - | - | 1,133,842 | D | |||
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 49,701 | $45.35 | 1,133,842 | D | S |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 34,405 | $45.35 | 821,752 | I | S |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 83,066 | $46.41 | 1,050,776 | D | S |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 57,502 | $46.41 | 764,250 | I | S |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | - | - | 1,050,599 | D | |||
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 177 | $47.01 | 1,050,599 | D | S |
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | - | - | 764,127 | I | |||
| 30 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 123 | $47.01 | 764,127 | I | S |
| 18 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 49,479 | $41.59 | 1,224,718 | D | S |
| 18 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 24,370 | $41.59 | 876,437 | I | S |
| 18 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 40,907 | $43.00 | 1,183,811 | D | S |
| 18 Sep, 2025 | Venture Capital Vi, L.P. Versant | - | - | 856,289 | I | |||
| 18 Sep, 2025 | Venture Capital Vi, L.P. Versant | Common Stock | D | 20,148 | $43.00 | 856,289 | I | S |